Celularity Inc. Amortization of Intangible Assets
Celularity Inc. (CELU) reported Amortization of Intangible Assets of $1.49 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-04-30
- Celularity Inc. amortization of intangible assets for the quarter ending 2025-03-31 was $368.00K, a 32.60% decline year-over-year.
- Celularity Inc. amortization of intangible assets for the quarter ending 2024-12-31 was $376.00K, a 32.01% decline year-over-year.
- Celularity Inc. amortization of intangible assets for the quarter ending 2024-09-30 was $375.00K, a 32.19% decline year-over-year.
- Celularity Inc. amortization of intangible assets for the quarter ending 2024-06-30 was $456.00K, a 16.48% decline year-over-year.
- Celularity Inc. amortization of intangible assets for fiscal 2025 was $1.49M, a 14.83% decline from fiscal 2024.
- Celularity Inc. amortization of intangible assets for fiscal 2024 was $1.75M, a 20.06% decline from fiscal 2023.
- Celularity Inc. amortization of intangible assets for fiscal 2023 was $2.19M, a 0.00% change from fiscal 2022.
- Celularity Inc. amortization of intangible assets for fiscal 2022 was $2.19M, a 0.05% increase from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2025-12-31 | $1.49M 10-K · filed 2026-04-30 | |||
| 2025-03-31 | $368.00K 10-Q · filed 2025-08-29 | $744.00K derived: sum of 2 quarters · filed 2026-04-30 | $1.12M derived: sum of 3 quarters · filed 2026-04-30 | $1.57M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $376.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30 | $751.00K derived: sum of 2 quarters · filed 2026-04-30 | $1.21M derived: sum of 3 quarters · filed 2026-04-30 | $1.75M 10-K · filed 2026-04-30 |
| 2024-09-30 | $375.00K 10-Q · filed 2024-12-06 | $831.00K derived: sum of 2 quarters · filed 2024-12-06 | $1.38M 10-Q · filed 2024-12-06 | $1.93M derived: sum of 4 quarters · filed 2025-08-29 |
| 2024-06-30 | $456.00K 10-Q · filed 2024-11-07 | $1.00M 10-Q · filed 2024-11-07 | $1.55M derived: sum of 3 quarters · filed 2025-08-29 | $2.11M derived: sum of 4 quarters · filed 2025-08-29 |
| 2024-03-31 | $546.00K 10-Q · filed 2025-08-29 | $1.10M derived: sum of 2 quarters · filed 2025-08-29 | $1.65M derived: sum of 3 quarters · filed 2025-08-29 | $2.20M derived: sum of 4 quarters · filed 2025-08-29 |
| 2023-12-31 | $553.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-08 | $1.11M derived: sum of 2 quarters · filed 2025-05-08 | $1.65M derived: sum of 3 quarters · filed 2025-05-08 | $2.19M 10-K · filed 2025-05-08 |
| 2023-09-30 | $553.00K 10-Q · filed 2024-12-06 | $1.10M derived: sum of 2 quarters · filed 2024-12-06 | $1.64M 10-Q · filed 2024-12-06 | $2.19M derived: sum of 4 quarters · filed 2024-12-06 |
| 2023-06-30 | $546.00K 10-Q · filed 2024-11-07 | $1.09M 10-Q · filed 2024-11-07 | $1.64M derived: sum of 3 quarters · filed 2024-11-07 | $2.19M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-03-31 | $541.00K 10-Q · filed 2024-10-16 | $1.09M derived: sum of 2 quarters · filed 2024-10-16 | $1.65M derived: sum of 3 quarters · filed 2024-10-16 | $2.19M derived: sum of 4 quarters · filed 2024-10-16 |
| 2022-12-31 | $553.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $1.11M derived: sum of 2 quarters · filed 2024-07-30 | $1.65M derived: sum of 3 quarters · filed 2024-07-30 | $2.19M 10-K · filed 2024-07-30 |
| 2022-09-30 | $553.00K 10-Q · filed 2024-01-03 | $1.10M derived: sum of 2 quarters · filed 2024-01-03 | $1.64M 10-Q · filed 2024-01-03 | $2.19M derived: sum of 4 quarters · filed 2024-01-03 |
| 2022-06-30 | $546.00K 10-Q · filed 2023-08-14 | $1.09M 10-Q · filed 2023-08-14 | $1.64M derived: sum of 3 quarters · filed 2023-08-14 | $2.19M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $541.00K 10-Q · filed 2023-05-22 | $1.09M derived: sum of 2 quarters · filed 2023-05-22 | $1.65M derived: sum of 3 quarters · filed 2023-05-22 | $2.19M derived: sum of 4 quarters · filed 2023-05-22 |
| 2021-12-31 | $552.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $1.10M derived: sum of 2 quarters · filed 2023-03-31 | $1.65M derived: sum of 3 quarters · filed 2023-03-31 | $2.19M 10-K · filed 2023-03-31 |
| 2021-09-30 | $553.00K 10-Q · filed 2022-11-10 | $1.10M derived: sum of 2 quarters · filed 2022-11-10 | $1.64M 10-Q · filed 2022-11-10 | $2.19M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $546.00K 10-Q · filed 2022-08-09 | $1.09M 10-Q · filed 2022-08-09 | $1.64M derived: sum of 3 quarters · filed 2022-08-09 | $2.42M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $541.00K 10-Q · filed 2022-05-16 | $1.09M derived: sum of 2 quarters · filed 2022-05-16 | $1.88M derived: sum of 3 quarters · filed 2022-05-16 | |
| 2020-12-31 | $551.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $1.33M derived: sum of 2 quarters · filed 2022-03-31 | $3.39M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $783.00K 10-Q · filed 2021-11-12 | $2.84M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |